Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
about
Adjuvant systemic therapy in older women with breast cancerManaging breast cancer in younger women: challenges and solutionsOsteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature reviewMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?RANKL/RANK: from bone loss to the prevention of breast cancerMetastatic colonization by circulating tumour cellsBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer.Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone scoreBRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.The best of both worlds - managing the cancer, saving the bone.Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysisOsteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls.Bone targeted treatments in cancer - The story so farSEOM Clinical Guideline for bone metastases from solid tumours (2016).Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical auditPlasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGFRAX and fracture prediction without bone mineral density.Management of bone disease in women after breast cancer.Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.Targeting metastasis.Low-trauma fractures without osteoporosis.Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.Management of Potential Long-Term Toxicities in Breast Cancer Patients.Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.The incidence of bone metastasis after early-stage breast cancer in Canada.The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
P2860
Q26741523-077CD72E-586A-4319-8836-8343E15F8642Q26771184-8C67485B-8EF2-4563-BD19-F97E575F6359Q27008336-F341199E-A6CE-4865-8A89-890D586DD154Q28068956-6B374D44-4CE4-48F9-8F43-561885908A38Q28075004-32423A68-EB4A-4F20-A072-5369AE56821AQ28076164-03FDDF83-F5DD-4209-B58D-E11A01AA89ABQ28081996-E812195C-0112-4EF5-9F2C-FB2CDFB39DC9Q30235173-062ED177-6517-4EAA-9C71-CDDC35C82226Q33606741-3D725362-0F6A-430E-ACFE-A3B042F621D6Q33792517-FC2B0C9F-77FA-4F81-B846-9DA4B759240CQ33798713-535BA9D7-550B-4649-A681-7F4E8ECAE41EQ33920055-51BD1152-E654-47C9-924F-41B9FC06026AQ36073645-0D0E933A-6CDB-4FBE-AD76-2F76115FF5D4Q36252676-E6370FC7-03E5-4108-8FA4-97F8588C2420Q36667402-B00D7090-15FD-451A-953D-3A59FBDD0196Q36677418-C241F56F-FA65-4D9B-85EF-D8E01359BA92Q37135281-C260EA96-1D67-45EF-8BBE-4A49E5BCD485Q37282924-8E28A0AC-9C5B-4342-A6BA-D1FEC87F77FDQ37337487-AF87106D-47CF-477F-B783-6931802FF211Q37475161-3470ECD7-E72C-4E57-97E6-D82B82AF7DE4Q37499975-B5BA4633-7286-4037-8D29-9E2F9453E0ADQ37699313-2FB5E8FE-0F47-4AA9-A04A-D537FF347D6FQ37706111-5FE6FB86-F7F6-491E-9207-30B721D15757Q37742180-0A0B812C-6DE4-4C40-B4F5-6E63B959278BQ38613173-F9294FD8-6E80-4417-AFE0-FE4D666B38F5Q38619529-25CD47B6-F039-4B94-8453-808FF090110FQ38669803-1FA3FE17-A297-4B0C-A4E1-E9F4D443A6AEQ38676979-7831B992-6A6F-45A6-811F-2FFD533FCB5EQ38682103-BD5AE1DA-F7DE-4A75-951E-71188F871025Q38786658-E49AC71D-0F08-40AB-88B9-25AD9D859EFBQ38978699-87FE244A-4450-455B-919C-60A4ECA397FCQ38991293-F091738F-2822-4BA6-A58F-ECAD784A16F7Q39013177-DA6BD6FE-5D35-476F-9CC0-90E104FA6A46Q39130990-2B010946-02F1-4FF6-9AFA-4FC0B3E361E8Q39157481-C5A308CE-556A-4B73-98F4-0C2E68811EC7Q39305824-AB2DEE58-2C6A-4488-A69A-80A006137C20Q39357548-77297F52-40FC-4F77-8239-400257418596Q39458785-546F08D1-4580-4DF3-83A1-64399A99C41AQ39847750-C8C9DCF3-420E-4D66-8F8C-AF8637092C03Q40188993-FEF90DAE-F69D-4A0C-80DF-F2F5AE18C816
P2860
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Adjuvant denosumab in breast c ...... ind, placebo-controlled trial.
@en
type
label
Adjuvant denosumab in breast c ...... ind, placebo-controlled trial.
@en
prefLabel
Adjuvant denosumab in breast c ...... ind, placebo-controlled trial.
@en
P2093
P921
P1433
P1476
Adjuvant denosumab in breast c ...... ind, placebo-controlled trial.
@en
P2093
Austrian Breast and Colorectal Cancer Study Group
Brigitte Mlineritsch
Christian F Singer
Christian Fesl
Christian Marth
Daniel Egle
Diether Manfreda
Douglas Warner
Elisabeth Melbinger
Ferdinand Haslbauer
P304
P356
10.1016/S0140-6736(15)60995-3
P407
P577
2015-05-31T00:00:00Z